Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.

You must read this new presentation from Porter Stansberry.

Marcus Schindler net worth and biography

Marcus Schindler Biography and Net Worth

EVP of Novo Nordisk A/S

Dr Schindler joined Novo Nordisk in January 2018 as Senior Vice President for External Innovation and Strategy.
From March 2018 to 2021 he was Senior Vice President for Global Drug Discovery and in March 2021 Dr Schindler was appointed Executive Vice President Research & Early Development and Chief Scientific Officer.

Prior to joining Novo Nordisk Dr Schindler was Vice President, head of Cardiovascular and Metabolic Diseases innovative Medicines (CVMD iMed) at AstraZeneca, Sweden. From 2009-2012 he was head of Research at (OSI) Prosidion, Oxford, UK. From 2000-2008 he worked in various leadership roles at Boehringer Ingelheim, Germany after having started his career with Glaxo Wellcome/GSK, UK in 1997. Dr Schindler holds a PhD from the University of Cambridge, UK.

Dr Schindler is an Adjunct Professor of Pharmacology at the University of Gothenburg, Sweden.

How old is Marcus Schindler?: Dr. Schindler is currently 58 years old. There are 7 older executives and no younger executives at Novo Nordisk A/S. Learn More on Marcus Schindler's age.
How do I contact Marcus Schindler?: The corporate mailing address for Dr. Schindler and other Novo Nordisk A/S executives is Novo Alle, Bagsvaerd G7, 2880. Novo Nordisk A/S can also be reached via phone at (454) 444-8888 and via email at [email protected]. Learn More on Marcus Schindler's contact information.
Has Marcus Schindler been buying or selling shares of Novo Nordisk A/S?: Marcus Schindler has not been actively trading shares of Novo Nordisk A/S over the course of the past ninety days. Learn More on Marcus Schindler's trading history.
Who are Novo Nordisk A/S's active insiders?: Novo Nordisk A/S's insider roster includes Lars Jørgensen (President), Karsten Knudsen (Exec. VP), and Marcus Schindler (EVP). Learn More on Novo Nordisk A/S's active insiders.

Marcus Schindler Insider Trading History at Novo Nordisk A/S

Marcus Schindler Buying and Selling Activity at Novo Nordisk A/S

Novo Nordisk A/S Company Overview

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Today's Range

Now: $110.30

$109.96

$110.88

50 Day Range

MA: $112.81

$99.82

$126.95

2 Week Range

Now: $110.30

$94.73

$148.15

Volume

1,765,632 shs

Average Volume

4,499,196 shs

Market Capitalization

$494.97 billion

P/E Ratio

35.70

Dividend Yield

0.68%

Beta

0.4

This company will win the AI race

From Porter & Company | Ad